Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1 (Currently amended): A pharmaceutical composition comprising one compound, ~~which~~ wherein the compound is a serotonin reuptake inhibitor, and ~~another~~ a second compound, ~~which~~ wherein the second compound is a H_3 receptor antagonist, inverse agonist or partial agonist having an affinity for the H_3 receptor below 0.5 μM.

Claim 2 (Currently amended):A pharmaceutical composition comprising a compound that is both a H_3 receptor antagonist, inverse agonist or partial agonist having an affinity for the H_3 receptor below 0.5 μM, and a serotonin reuptake inhibitor.

Claim 3 (Currently amended): A method of augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor, comprising administering to a patient in need thereof a therapeutically effective amount of a H_3 receptor antagonist, inverse agonist or partial agonist having an affinity for the H_3 receptor below 0.5 μM.

Claim 4 (Currently amended): A method of treating depression or an affective disorder, comprising administering a therapeutically effective amount of a H_3 receptor antagonist, inverse agonist or partial agonist having an affinity for the H_3 receptor below 0.5 μM to a patient being treated with a serotonin reuptake inhibitor and in need thereof.

Claim 5 (Previously presented): A method of treating depression or an affective disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 1.

Claim 6 (Currently amended): The method of claim 5, wherein the ~~compound~~ serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor.

Claim 7 (Currently amended): The method of claim 5, wherein the ~~compound~~ H_3 receptor antagonist, inverse agonist or partial agonist is selective for the H_3 receptor.

Claim 8 (Currently amended): The method of claim 5, wherein the second compound is an antagonist or an inverse agonist at the H_3 receptor.

Claim 9 (Currently amended): The method of claim 5 [[8]], wherein the second compound is a H_3 receptor antagonist.

Claim 10 (Currently amended): The method of claim [[6]] 5, wherein the serotonin reuptake inhibitor is ~~selected from~~ citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramine, femoxetine, or [[and]] clomipramine.

Claim 11 (Currently amended): The method of claim 5, wherein the H3 receptor ~~ligand~~ H_3 receptor antagonist, inverse agonist or partial agonist is ~~selected from~~ Thioperamide, Ciproxifan, Iodophenpropit, GR 175737, Iodoproxyfan, Proxifan, Perceptin, JB 98064, VUF 9153, A 304121, ABT923, ABT 834, A 923, A 320436, A 331440, A 349413, A 349821, A 417022, A 423579, A 424835, A 431404, AQ 0145, FUB 181, FUB 360, FUB 407, FUB 637, FUB 836, GR 168320, GSK 189254A, GSK 207040A, GT 2016, GT 2104, GT 2209, GT 2212, GT 2227, GT 2232, GT 2390, GT 2349, GT 2355, GT 2394, Imoproxifan, Impentamine, JNJ 5207852, NNC 0038 0000 1049, NNC 0038 0000 1202, SCH 50971, SCH 79687, UCL 1199, UCL 1283, UCL 1390, UCL 1409, UCL 1860, UCL 1972, UCL 2065, UCL 2138, UCL 2173, UCL 2283, Verongamine, VUF 4163, VUF 5000, or [[and]] VUF 5182.

Claim 12 (Previously presented): The pharmaceutical composition according to claim 1, further comprising a pharmaceutically acceptable carrier or diluent.

Claim 13 (Currently amended): The pharmaceutical composition according to claim 1, wherein the serotonin reuptake inhibitor ~~used~~ is a selective serotonin reuptake inhibitor.

Claim 14 (Previously presented): The pharmaceutical composition according to claim 1, wherein the H_3 antagonist, inverse agonist or partial agonist is selective for the H_3 receptor.

Claim 15 (Currently amended): The pharmaceutical composition according to claim 1, wherein the second compound ~~H_3 ligand~~ is a H_3 receptor antagonist.

Claim 16 (Currently amended): The pharmaceutical composition according to claim 1, wherein the serotonin uptake inhibitor is ~~selected from~~ citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, duloxetine, vilazodone, nefazodone, imipramine, femoxetine, or [[and]] clomipramine.

Claim 17 (Currently amended): The pharmaceutical composition according to claim 1, wherein the H_3 ~~ligand~~ antagonist, inverse agonist or partial agonist is ~~selected from from~~ Thioperamide, Ciproxifan, Iodophenpropit, GR 175737, Iodoproxyfan, Proxifan, Perceptin, JB 98064, VUF 9153, A 304121, ABT923, ABT 834, A 923, A 320436, A 331440, A 349413, A 349821, A 417022, A 423579, A 424835, A 431404, AQ 0145, FUB 181, FUB 360, FUB 407, FUB 637, FUB 836, GR 168320, GSK 189254A, GSK 207040A, GT 2016, GT 2104, GT 2209, GT 2212, GT 2227, GT 2232, GT 2390, GT 2349, GT 2355, GT 2394, Imoproxifan, Impentamine, JNJ 5207852, NNC 0038 0000 1049, NNC 0038 0000 1202, SCH 50971, SCH 79687, UCL 1199, UCL 1283, UCL 1390, UCL 1409, UCL 1860, UCL 1972, UCL 2065, UCL 2138, UCL 2173, UCL 2283, Verongamine, VUF 4163, VUF 5000, or [[and]] VUF 5182.

Claim 18 (Currently amended): The method of claim 5, wherein the ~~active ingredients~~ serotonin uptake inhibitor and H_3 antagonist, inverse agonist or partial agonist are administered by simultaneous administration.

Claim 19 (Currently amended): The method of claim 5, wherein the ~~active ingredients~~ serotonin uptake inhibitor and H_3 antagonist, inverse agonist or partial agonist are administered in the same unit dosage form.

Claim 20 (Currently amended): The method of claim 5, wherein the ~~active ingredients~~ serotonin uptake inhibitor and H_3 antagonist, inverse agonist or partial agonist are administered by sequential administration.

Claim 21 (Currently amended): The method of claim 5, wherein the ~~active ingredients~~ serotonin uptake inhibitor and H_3 antagonist, inverse agonist or partial agonist are administered in discrete dosage forms.

Claim 22 (Currently amended): A method for identifying compounds useful for the treatment of depression or an affective disorder, comprising, in any order:

(a) measuring the ability of ~~test~~ compounds to inhibit serotonin reuptake and selecting the compounds that have an IC_{50} value below 50 nM;

(b) measuring the affinity of ~~test~~ selected compounds to the H_3 receptor and further selecting the compounds that have an affinity for the H_3 receptor below 0.5 μM,

and thereafter measuring the efficacy of the selected compounds at the H_3 receptor and further selecting the compounds which are antagonists, inverse agonists or partial agonists at the H_3 receptor.

Claim 23 (Previously presented): The method according to claim 22 wherein the compound has an affinity in step (b) of less than 50 nM.

Claim 24 (Previously presented): The method according to claim 23, wherein the compound has an affinity in step (b) of less than 10 nM.

Claim 25 (Currently amended): A compound that inhibits serotonin reuptake and has an IC_{50} value below 50 nM; and has an affinity to the H_3 receptor below 0.5 μM.

Claim 26 (Previously presented): A method of treating depression or an affective disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 2.

Claim 27 (Currently amended): The method of claim 26, wherein the compound ~~serotonin reuptake inhibitor~~ is a selective serotonin reuptake inhibitor.

Claim 28 (Currently amended): The method of claim 26, wherein the compound ~~H_3 receptor antagonist, inverse agonist or partial agonist~~ is selective for the H_3 receptor.

Claim 29 (Currently amended): The method of claim 26, wherein the compound ~~H_3 receptor antagonist, inverse agonist or partial agonist~~ is an antagonist or an inverse agonist at the H_3 receptor.

Claim 30 (Currently amended): The method of claim 29, wherein the compound ~~H_3 receptor antagonist, inverse agonist or partial agonist~~ is a H_3 receptor antagonist.

Claim 31 (Previously presented): The pharmaceutical composition according to claim 2, further comprising a pharmaceutically acceptable carrier or diluent.

Claim 32 (Currently amended): The pharmaceutical composition according to claim 2, wherein the compound ~~H_3 ligand~~ is a H_3 receptor antagonist.

Claim 33 (Currently amended): The method of claim 4, wherein the affective disorder is ~~selected from~~ an anxiety disorder ~~disorders~~, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, an eating disorder ~~disorders~~, a phobia ~~phobias~~, dysthymia, premenstrual syndrome, a cognitive disorder ~~disorders~~, an impulse control disorder ~~disorders~~, attention deficit hyperactivity disorder, or drug abuse ~~or any other disorder responsive to a serotonin reuptake inhibitor~~.

Claim 34 (Currently amended): The method of claim 33, wherein the eating disorder is ~~selected from,~~ bulimia, anorexia, or [[and]] obesity.

Claim 35 (Currently amended): The method of claim 5, wherein the affective disorder is ~~selected from~~ an anxiety disorder ~~disorders~~, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, an eating disorder ~~disorders~~, a phobia ~~phobias~~, dysthymia, premenstrual syndrome, a cognitive disorder ~~disorders~~, an impulse control disorder ~~disorders~~, attention deficit hyperactivity disorder, or drug abuse ~~or any other disorder responsive to a serotonin reuptake inhibitor~~.

Claim 36 (Currently amended): The method of claim 35, wherein the eating disorder is ~~selected from,~~ bulimia, anorexia, or [[and]] obesity.

Claim 37 (Currently amended): The method of claim 22, wherein the affective disorder is ~~selected from~~ an anxiety disorder ~~disorders~~, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, an eating disorder ~~disorders~~, a phobia ~~phobias~~, dysthymia, premenstrual syndrome, a cognitive disorder ~~disorders~~, an impulse control disorder ~~disorders~~, attention deficit hyperactivity disorder, or drug abuse ~~or any other disorder responsive to a serotonin reuptake inhibitor~~.

Claim 38 (Currently amended): The method of claim 37, wherein the eating disorder is ~~selected from,~~ bulimia, anorexia, or [[and]] obesity.

Claim 39 (Currently amended): The method of claim 26, wherein the affective disorder is ~~selected from~~ an anxiety disorder ~~disorders~~, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, an eating disorder ~~disorders~~, a phobia ~~phobias~~, dysthymia, premenstrual

syndrome, a cognitive disorder ~~disorders~~, an impulse control disorder ~~disorders~~, attention deficit hyperactivity disorder, or drug abuse~~ or any other disorder responsive to a serotonin reuptake inhibitor~~.

Claim 40 (Currently amended): The method of claim 39, wherein the eating disorder is ~~selected from,~~ bulimia, anorexia, or [[and]] obesity.

Claim 41 (Previously presented): The compound of claim 25, wherein the compound has an affinity to the H_3 receptor of less than 50 nM.

Claim 42 (Previously presented): The compound of claim 41, wherein the compound has an affinity to the H_3 receptor of less than 10 nM.